Read by QxMD icon Read

Annals of Hematology

Hisashi Ishida, Akihiro Iguchi, Michinori Aoe, Takahide Takahashi, Kosuke Tamefusa, Kiichiro Kanamitsu, Kaori Fujiwara, Kana Washio, Takehiro Matsubara, Hirokazu Tsukahara, Masashi Sanada, Akira Shimada
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Although the cure rate of ALL has greatly improved, a considerable number of patients suffer from relapse of leukemia. Therefore, ALL remains the leading cause of death from cancer during childhood. To improve the cure rate of these patients, precisely detecting patients with high risk of relapse and incorporating new targeted therapies are urgently needed. This study investigated inexpensive, rapid, next-generation sequencing of more than 150 cancer-related genes for matched diagnostic, remission, and relapse samples of 17 patients (3 months to 15 years old) with relapsed ALL...
November 17, 2018: Annals of Hematology
Hanny Al-Samkari, Elizabeth M Van Cott, David J Kuter
The thrombopoietin receptor agonist romiplostim is used for the long-term treatment of chronic immune thrombocytopenia (ITP). ITP patients have an increased thrombotic risk, which could be exacerbated if romiplostim increased platelet hyperreactivity or caused spontaneous platelet aggregation. To investigate this possibility, this study examined platelet function in romiplostim-treated ITP patients and healthy subjects. Light transmission platelet aggregometry utilizing arachidonic acid, collagen, epinephrine, ristocetin, ADP, and saline (to assess spontaneous aggregation) was performed for each subject...
November 17, 2018: Annals of Hematology
Sandra De Barros, Flora Vayr, Fabien Despas, Mathilde Strumia, Clémentine Podevin, Martin Gauthier, Eric Delabesse, Jean-Marc Soulat, Guy Laurent, Françoise Huguet, Fabrice Herin
Patients with chronic myeloid leukemia treated with breakpoint cluster region-Abelson tyrosine kinase inhibitors are likely to survive in excess of 20 years after diagnosis. New challenges appear as we consider life after the disease, including professional challenges and the social reintegration of patients. The purpose of this study was to determine the impact of chronic myeloid leukemia on employment within 2 years after diagnosis. This prospective, observational study included patients diagnosed with chronic myeloid leukemia and treated with a tyrosine kinase inhibitor...
November 17, 2018: Annals of Hematology
Valentín García-Gutiérrez, Dragana Milojkovic, Juan Carlos Hernandez-Boluda, Simone Claudiani, María Luisa Martin Mateos, Luis Felipe Casado-Montero, Gloria González, Antonio Jimenez-Velasco, Concepcion Boque, Alejandra Martinez-Trillos, Isabel Mata Vázquez, Ángel Ramírez Payer, Alicia Senín, Elena Amustio Díez, Abelardo Bárez García, Guiomar Bautista Carrascosa, Guillermo Ortí, Beatriz Cuevas Ruiz, Maria Ángeles Fernández, María Del Carmen García Garay, Pilar Giraldo, Jose María Guinea, Natalia De Las Heras Rodríguez, Nuria Hernán, Ana Iglesias Pérez, Miguel Piris-Villaespesa, Jose Luis López Lorenzo, Josep Maria Martí Martí-Tutusaus, Rolando Omar Vallansot, Fernando Ortega Rivas, Jose Manuel Puerta, Maria Jose Ramirez, Esperanza Romero, Andres Romo, Ana Rosell, Silvanna Saavedra Saavedra, Ana Sebrango, José Tallon, Sandra Valencia, Angeles Portero, Juan Luis Steegmann
Bosutinib is a second-generation tyrosine kinase inhibitor (2GTKI) approved at 400 mg once daily (QD) as first-line therapy in patients with chronic myeloid leukemia (CML) patients and at 500 mg QD in patients who are resistant to or intolerant of prior therapy. In clinical practice, bosutinib is often given to patients who have failed imatinib, nilotinib, and dasatinib (i.e., as fourth-line treatment), despite the limited data on its clinical benefit in this setting. We have retrospectively evaluated the results of bosutinib in a series of 62 CML patients who have failed to prior treatment with all three, imatinib, nilotinib, and dasatinib...
November 16, 2018: Annals of Hematology
Masatoshi Sakurai, Daiki Karigane, Hidenori Kasahara, Tomohiko Tanigawa, Akaru Ishida, Hiroshi Murakami, Masao Kikuchi, Sumiko Kohashi
The proportion of elderly patients with diffuse large B cell lymphoma (DLBCL) appears to be increasing, with outcomes varying widely because of the patients' heterogeneity. Geriatric assessment is used to predict prognosis in elderly patients with DLBCL, but the utility of two simple screening tools for patients with DLBCL, the Flemish version of the Triage Risk Screening Tool (fTRST) and G8, has remained to be elucidated. We retrospectively assessed patients using fTRST and G8, and evaluated the impacts of the scores on survival outcomes in older patients with newly diagnosed DLBCL...
November 15, 2018: Annals of Hematology
Seiichi Okabe, Yuko Tanaka, Tetsuzo Tauchi, Kazuma Ohyashiki
Multiple myeloma (MM) is a uniformly fatal disorder of B cells characterized by the accumulation of abnormal plasma cells. Phosphoinositide 3-kinase (PI3K) signaling pathways play a critical regulatory role in MM pathology. Copanlisib, also known as BAY80-6946, is a potent PI3Kα and δ inhibitor. In this study, we investigated the efficacy of copanlisib and a proteasome inhibitor using MM cell lines and primary samples. The p110α and δ catalytic subunits of the class PI3K increased, and carfilzomib activity reduced in the presence of a supernatant from the feeder cell line, HS-5...
November 15, 2018: Annals of Hematology
Giovanni Martino, Andrea Marra, Stefano Ascani, Paolo Sportoletti
No abstract text is available yet for this article.
November 13, 2018: Annals of Hematology
Zaineb Akram, Parvez Ahmed, Sachiko Kajigaya, Tariq Mahmood Satti, Humayoon Shafique Satti, Qamar Un Nisa Chaudhary, Fernanda Gutierrez-Rodrigues, Pilar F Ibanez, Xingmin Feng, Syed Kamran Mahmood, Tariq Ghafoor, Nighat Shahbaz, Mehreen Ali Khan, Aneesa Sultan
Aplastic anemia (AA) is the most serious non-malignant blood disorder in Pakistan, ranked second in prevalence, after thalassemia. We investigated various epidemiological, clinical, and genetic factors of AA in a Pakistani cohort of 214 patients reporting at our hospital between June 2014 and December 2015. A control group of 214 healthy subjects was included for comparison of epidemiological and clinical features. Epidemiological data revealed 2.75-fold higher frequency of AA among males. A single peak of disease onset was observed between ages 10 and 29 years followed by a steady decline...
November 13, 2018: Annals of Hematology
Vlatko Pejsa, Marko Lucijanic, Zeljko Jonjic, Zeljko Prka, Gorana Vukorepa
No abstract text is available yet for this article.
November 13, 2018: Annals of Hematology
Se-Il Go, Sungwoo Park, Myoung Hee Kang, Hoon-Gu Kim, Hye Ree Kim, Gyeong-Won Lee
We evaluated the association between the prognostic nutritional index (PNI) and the clinical features of diffuse large B cell lymphoma (DLBCL) and developed a novel prognostic model using a nomogram including the PNI and other biomarkers for cancer cachexia. A total of 228 DLBCL patients treated with first-line R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) were retrospectively reviewed. PNI was calculated as 10 × serum levels of albumin (g/dL) + 0.005 × absolute lymphocyte count (/mm3 )...
November 9, 2018: Annals of Hematology
Amer M Zeidan, Smith Giri, Michelle DeVeaux, Samir K Ballas, Vu H Duong
The impact of iron chelation therapy (ICT) on overall survival (OS) and progression to acute myeloid leukemia (AML) in patients with iron overload and International Prognostic Scoring System low- or intermediate-risk myelodysplastic syndromes (MDS) is not well understood. We conducted a systematic review and meta-analysis of published studies of ICT in patients with MDS to better elucidate these relationships. We searched PubMed, EMBASE, Cochrane databases, and the World Health Organization Clinical Trial Registry for studies reporting the impact of ICT on OS in patients with low- or intermediate-risk MDS...
November 9, 2018: Annals of Hematology
Alessandra Serrao, Martina Canichella, Maria Lucia De Luca, Germana Tartaglia, Giorgia Annechini, Gianna Maria D'Elia, Alessandro Pulsoni
No abstract text is available yet for this article.
November 9, 2018: Annals of Hematology
Sujana Biswas, Arijit Nag, Kanjaksha Ghosh, Rudra Ray, Kaushik Roy, Anish Bandyopadhyay, Maitreyee Bhattacharyya
Thalassaemia are the most common inherited autosomal recessive single gene disorders characterized by chronic hereditary haemolytic anaemia due to the absence or reduced synthesis of one or more of the globin chains. Haemoglobin E-β thalassaemia is the genotype responsible for approximately one half of all severe beta-thalassaemia worldwide. This study proposes to evaluate the effect of various molecular parameters on the response of hydroxyurea. Hydroxyurea was started at an initial dose of 10 mg/kg of body weight/day on 110 transfusion-dependent HbE-β thalassaemia patients...
November 9, 2018: Annals of Hematology
Masako Yokoo, Kensuke Kojima, Haruna Sano, Keita Kai, Fumiko Arakawa, Koichi Ohshima, Taketo Matsunaga, Shinya Kimura
No abstract text is available yet for this article.
November 8, 2018: Annals of Hematology
Amin T Turki, Wolfgang Lamm, Christoph Schmitt, Evren Bayraktar, Ferras Alashkar, Martin Metzenmacher, Philipp Wohlfahrth, Dietrich W Beelen, Tobias Liebregts
Despite significant advances in the treatment of complications requiring intensive care unit (ICU) admission, ICU mortality remains high for patients after allogeneic stem cell transplantation. We evaluated the role of thrombocytopenia and poor graft function in allogeneic stem cell recipients receiving ICU treatments along with established prognostic ICU markers in order to identify patients at risk for severe complications. At ICU admission, clinical and laboratory data of 108 allogeneic stem cell transplanted ICU patients were collected and retrospectively analyzed...
November 7, 2018: Annals of Hematology
Luhan Swart, Nicolas Novitzky, Zainab Mohamed, Jessica Opie
Human immunodeficiency virus (HIV) is associated with an increased risk of developing Hodgkin lymphoma (HL). South Africa (SA) has the highest HIV prevalence rate in the world. There is currently no outcome-based data for HIV-associated HL from SA. A bone marrow database was compiled of all bone marrow biopsies (BMB) reported at National Health Laboratory Service (NHLS) Groote Schuur Hospital (GSH) between January 2005 and December 2012. Patients who had a BMB performed for staging of HL or where HL was diagnosed on the BMB were included for further analysis...
November 5, 2018: Annals of Hematology
Hannah Levavi, Doyun Park, Joshua Tannenbaum, Amir Steinberg
No abstract text is available yet for this article.
November 3, 2018: Annals of Hematology
Elisabetta Metafuni, Marianna Criscuolo, Teresa Spanu, Simona Sica
No abstract text is available yet for this article.
November 1, 2018: Annals of Hematology
Alain Mina, Leyla Shune, Haitham Abdelhakim, Tara L Lin, Sid Ganguly, Andrea Baran, Anurag Singh, Sunil Abhyankar, Joseph P McGuirk, Dennis Allin, Omar S Aljitawi
Umbilical cord blood (UCB) transplantation is a promising option for hematopoietic stem cell transplantation in patients with hematologic malignancies who lack an HLA-matched sibling or well-matched unrelated donor; however, it has a higher incidence of delayed or failed engraftment because cell doses are low and bone marrow homing is inefficient. We have demonstrated that pre-treating irradiated immune-deficient mice with hyperbaric oxygen (HBO) prior to UCB CD34+ cell transplantation lowered host systemic erythropoietin (EPO) and improved UCB CD34+ cell homing and engraftment...
October 31, 2018: Annals of Hematology
Zihang Chen, Xueqin Deng, Yunxia Ye, Limin Gao, Wenyan Zhang, Weiping Liu, Sha Zhao
The prognostic value of tumour-infiltrating T lymphocytes (TIL-Ts) has been demonstrated in many solid tumours but remained unclear in diffuse large B cell lymphoma (DLBCL). We conducted a retrospective cohort study reviewing the TIL-Ts proportion and CD4:CD8 of 66 de novo DLBCL by flow cytometry to construct a risk stratification based on TIL-Ts-related prognostic factors. In univariate analysis, low TIL-Ts (< 14%) was significantly related to shorter survival (HR = 2.58, 95% CI 1.11-5.99, p = 0...
October 30, 2018: Annals of Hematology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"